{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:23:25Z","timestamp":1791912205563,"version":"4.3.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1445900"],"award-info":[{"award-number":["24ZR1445900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["SHSMU-ZDCX20211002"],"award-info":[{"award-number":["SHSMU-ZDCX20211002"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug-induced hypersensitivity reaction often requiring prolonged corticosteroid (CS) treatment, yet tapering is challenging due to the risk of relapse. In this retrospective single-centre case series, we evaluated the effectiveness and safety of selective Janus kinase (JAK) inhibitors in facilitating CS tapering in patients with moderate-to-severe refractory DRESS and in ameliorating pruritus. Six patients (median age 35\u2005years, range 9\u201370, five female) received baricitinib or abrocitinib with CS between July 2023 and June 2024. All achieved rapid clinical improvement, with generalized lesion resolution and a reduction in pruritus by &amp;gt; 3 points on the Worst Itch Numerical Rating Scale. Successful initial CS tapering occurred within 7\u201312\u2005days. Four patients discontinued CS completely within 28\u201362\u2005days, while two continued with low-dose CS due to primary autoimmune disease. Serum cytokines, particularly interleukin-5, decreased markedly following JAK inhibition. No severe adverse events occurred, including in patients with pancytopenia or hepatic dysfunction. JAK inhibitors appear to be effective and well-tolerated for promoting CS tapering in patients with refractory DRESS. Larger, controlled studies would be useful to confirm these findings.<\/jats:p>","DOI":"10.1093\/ced\/llag072","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:51:24Z","timestamp":1770382284000},"page":"1076-1082","source":"Crossref","is-referenced-by-count":3,"title":["Janus kinase 1 and 1\/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a\u00a0case series"],"prefix":"10.1093","volume":"51","author":[{"given":"Weijun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]},{"name":"Dermatology Hospital of Jiangxi Province, Jiangxi Provincial Clinical Research Center for Skin Diseases, Candidate Branch of National Clinical Research Center for Skin Diseases, Dermatology Institute of Jiangxi Province, The Affiliated Dermatology Hospital of Nanchang University , Nanchang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-9735","authenticated-orcid":false,"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2026052522583666800_llag072-B1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026052522583666800_llag072-B2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jamadermatol.2023.4450","article-title":"Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus","volume":"160","author":"Br\u00fcggen","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026052522583666800_llag072-B3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaip.2023.09.036","article-title":"The usefulness of omalizumab in low response to corticosteroids DRESS syndrome: a case series","volume":"12","author":"Ben Said","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026052522583666800_llag072-B4","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.jaip.2023.08.028","article-title":"Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series","volume":"11","author":"Dubin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026052522583666800_llag072-B5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"2026052522583666800_llag072-B6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026052522583666800_llag072-B7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"},{"key":"2026052522583666800_llag072-B8","doi-asserted-by":"crossref","first-page":"650295","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026052522583666800_llag072-B9","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag072\/66801118\/llag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1076\/66801118\/llag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1076\/66801118\/llag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:58:43Z","timestamp":1779764323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1076\/8466590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":9,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag072","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,9]]}}}